Silva Pharmaceuticals Limited (DSE:SILVAPHL)
Bangladesh · Delayed Price · Currency is BDT 13.50
-0.20 (-1.46%)
At close: Sep 3, 2026
Silva Pharmaceuticals Ratios and Metrics
Market cap in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 2, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
| 1,843 | 1,461 | 1,952 | 2,948 | 3,290 | 2,689 | |
Market Cap Growth | 4.65% | -25.17% | -33.80% | -10.37% | 22.34% | 7.65% |
Enterprise Value | 1,761 | 1,362 | 1,820 | 2,813 | 3,132 | 2,480 |
Last Close Price | 13.50 | 10.70 | 14.16 | 21.29 | 23.42 | 18.63 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 2, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
PE Ratio | - | - | - | 89.14 | 32.17 | 22.44 |
PS Ratio | 5.59 | 3.81 | 3.26 | 4.11 | 4.22 | 3.36 |
PB Ratio | 0.91 | 0.69 | 0.87 | 1.26 | 1.42 | 1.18 |
P/TBV Ratio | 0.92 | 0.69 | 0.87 | 1.26 | 1.42 | 1.19 |
P/FCF Ratio | - | 225.07 | - | - | - | 32.71 |
P/OCF Ratio | - | 107.73 | 570.94 | 42.06 | 20.45 | 16.87 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 2, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
EV/Sales Ratio | 5.34 | 3.55 | 3.04 | 3.92 | 4.02 | 3.10 |
EV/EBITDA Ratio | - | - | 172.70 | 26.22 | 17.96 | 11.96 |
EV/EBIT Ratio | - | - | - | 62.82 | 28.02 | 17.45 |
EV/FCF Ratio | - | 209.82 | - | - | - | 30.16 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 2, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Debt / Equity Ratio | 0.00 | 0.02 | 0.02 | 0.03 | 0.04 | 0.02 |
Debt / EBITDA Ratio | - | - | 4.29 | 0.56 | 0.55 | 0.20 |
Debt / FCF Ratio | - | 4.87 | - | - | - | 0.52 |
Net Debt / Equity Ratio | -0.04 | -0.03 | -0.03 | -0.05 | -0.07 | -0.10 |
Net Debt / EBITDA Ratio | 0.92 | 1.13 | -7.13 | -1.11 | -0.93 | -1.10 |
Net Debt / FCF Ratio | 5.84 | -10.97 | 2.54 | 7.15 | 9.67 | -2.77 |
Asset Turnover | 0.15 | 0.16 | 0.24 | 0.28 | 0.31 | 0.33 |
Inventory Turnover | 0.57 | 0.61 | 0.89 | 1.00 | 1.04 | 1.07 |
Quick Ratio | 7.88 | 5.97 | 5.17 | 5.11 | 3.76 | 6.13 |
Current Ratio | 21.19 | 14.90 | 12.67 | 11.61 | 7.70 | 12.15 |
Return on Equity (ROE) | -7.37% | -6.09% | -2.81% | 1.42% | 4.45% | 5.36% |
Return on Assets (ROA) | -3.98% | -3.24% | -1.23% | 1.11% | 2.80% | 3.62% |
Return on Invested Capital (ROIC) | -7.28% | -5.73% | -2.20% | 1.34% | 4.66% | 5.56% |
Return on Capital Employed (ROCE) | -6.80% | -5.50% | -2.10% | 1.90% | 4.60% | 6.00% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 2, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Earnings Yield | -8.37% | -9.10% | -3.30% | 1.12% | 3.11% | 4.46% |
FCF Yield | -0.76% | 0.44% | -1.52% | -0.57% | -0.51% | 3.06% |
Dividend Yield | - | - | 0.71% | 0.47% | 1.28% | 2.68% |
Payout Ratio | - | - | - | 75.66% | 46.70% | 39.46% |
Total Shareholder Return | - | - | 0.71% | 0.47% | 1.28% | 2.68% |